ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination

doi:10.3969/j.issn.1673-8640.2023.12.006

Abstract

Abstract:

Objective To investigate the characteristics of antinuclear antibody（ANA） profiles in patients with corona virus disease 2019（COVID-19） and the influence of serum heat-inactivation on ANA determination. Methods Totally，49 patients with autoimmune disease（AID） from Baoshan Branch of Huashan Hospital of Fudan University from March to May 2022 were enrolled among whom the characteristics of ANA positive results were analyzed. After heating sera with metal bath at 56 ℃ for 30 min（observation group），the differences in the results of ANA by indirect immunofluorescent assay and line immunoassay between observation group and control group（untreated sera） were compared. Results The ANA determination was positive in 48.98% of patients' sera，with 22（91.7%） being positive with a low titer（≤1∶320） and 2（8.3%） being positive with a middle titer（≥1∶1 000）. ANA patterns were diverse，including 6 cases of AC-4（fine speckled），5 cases of AC-1（homogeneous），2 cases of AC-3（centromere），1 case of AC-10（punctate nucleolar），3 cases of AC-20（cytoplasmic fine speckled） and 7 cases of mixed patterns. There was no statistical significance in ORF1ab gene，N gene Ct values and the nucleic acid conversion time between ANA positive and ANA negative groups（P>0.05）. The positive rate of ANA was the highest in COVID-19 patients with AID（55.6%），which was not significantly different from that in patients with non-AID（48.4%） and without underlying diseases（44.4%）（P>0.05）. There was no statistical significance in types and intensity of ANA patterns and specific antibodies between observation and control groups with positive ANA results，and the results of ANA negative ones stayed negative after serum heat inactivation. Conclusions Positive ANA shows limited impact on disease outcome. Serum heat inactivation at 56 ℃ for 30 min will not change the results of ANA determination，patterns，titers，target antigen determination in patients with COVID-19.

Key words: Antinuclear antibody, Heat inactivation, Indirect immunofluorescent assay, Corona virus disease 2019

CLC Number:

R446.1

XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination[J]. Laboratory Medicine, 2023, 38(12): 1141-1146.

Figures/Tables 4

References 28

[1]	PEKER B O, ENER A G, KAPTAN AYDOMU F. Antinuclear antibodies(ANAs)detected by indirect immunofluorescence(IIF)method in acute COVID-19 infection;future roadmap for laboratory diagnosis[J]. J Immunol Methods, 2021, 499:113174. DOI URL
[2]	SAAD M A, ALFISHAWY M, NASSAR M, et al. COVID-19 and autoimmune diseases:a systematic review of reported cases[J]. Curr Rheumatol Rev, 2021, 17(2):193-204.
[3]	MERONI P L, SCHUR P H. ANA screening:an old test with new recommendations[J]. Ann Rheum Dis, 2010, 69(8):1420-1422. DOI URL
[4]	刘洁, 赵剑虹, 高艳, 等. 加温灭活对SARS-CoV-2咽拭子样本核酸检测结果的影响[J]. 检验医学, 2020, 35(5):405-408.
[5]	中华人民共和国国家卫生健康委员会办公厅, 中华人民共和国国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 中国医药, 2022, 17(4):481-487.
[6]	DAMOISEAUX J, ANDRADE L E C, CARBALLO O G, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns:the International Consensus on ANA patterns(ICAP) perspective[J]. Ann Rheum Dis, 2019, 78(7):879-889. DOI URL
[7]	CHAN E K L, VON MÜLLEN C A, FRITZLER M J, et al. The International Consensus on ANA Patterns(ICAP) in 2021-the 6th workshop and current perspectives[J]. J Appl Lab Med, 2022, 7(1):322-330. DOI URL
[8]	VOJDANI A, KHARRAZIAN D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases[J]. Clin Immunol, 2020, 217:108480. DOI URL
[9]	SALLE V. Coronavirus-induced autoimmunity[J]. Clin Immunol, 2021, 226:108694. DOI URL
[10]	KANDUC D, SHOENFELD Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes:implications for the vaccine[J]. Immunol Res, 2020, 68(5):310-313. DOI
[11]	ZUO Y, ESTES S K, ALI R A, et al. Prothrombotic antiphospholipid antibodies in COVID-19[J]. medRxiv, 2020, 2020:20131607.
[12]	TAN C W, LOW J G H, WONG W H, et al. Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability[J]. Am J Hematol, 2020, 95(7):E156-E158.
[13]	BASTARD P, ROSEN LB, ZHANG Q, et al. Autoantibodies against type Ⅰ IFNs in patients with life-threatening COVID-19[J]. Science, 2020, 370(6515):eabd4585.
[14]	MULLER S, RADIC M. Oxidation and mitochondrial origin of NET DNA in the pathogenesis of lupus[J]. Nat Med, 2016, 22(2):126-127. DOI PMID
[15]	APEL F, ZYCHLINSKY A, KENNY E F. The role of neutrophil extracellular traps in rheumatic diseases[J]. Nat Rev Rheumatol, 2018, 14(8):467-475. DOI PMID
[16]	WIGERBLAD G, KAPLAN M J. NETs spread ever wider in rheumatic diseases[J]. Nat Rev Rheumatol, 2020, 16(2):73-74. DOI PMID
[17]	ALI R A, GANDHI A A, MENG H, et al. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome[J]. Nat Commun, 2019, 10(1):1916. DOI PMID
[18]	NARASARAJU T, TANG B M, HERRMANN M, et al. Neutrophilia and NETopathy as key pathologic drivers of progressive lung impairment in patients with COVID-19[J]. Front Pharmacol, 2020, 11:870. DOI PMID
[19]	TOMAR B, ANDERS H J, DESAI J, et al. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19[J]. Cells, 2020, 9(6):1383. DOI URL
[20]	BARNES B J, ADROVER J M, BAXTER-STOLTZFUS A, et al. Targeting potential drivers of COVID-19:neutrophil extracellular traps[J]. J Exp Med, 2020, 217(6):e20200652.
[21]	PASCOLINI S, VANNINI A, DELEONARDI G, et al. COVID-19 and immunological dysregulation:can autoantibodies be useful?[J]. ClinTransl Sci, 2021, 14(2):502-508.
[22]	GAZZARUSO C, CARLO STELLA N, MARIANI G, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia[J]. Clin Rheumatol, 2020, 39(7):2095-2097. DOI PMID
[23]	LERMA L A, CHAUDHARY A, BRYAN A, et al. Prevalence of autoantibody responses in acute coronavirus disease 2019(COVID-19)[J]. J Transl Autoimmun, 2020, 3:100073. DOI URL
[24]	SACCHI M C, TAMIAZZO S, STOBBIONE P, et al. SARS-CoV-2 infection as a trigger of autoimmune response[J]. ClinTransl Sci, 2021, 14(3):898-907.
[25]	CHANG S E, FENG A, MENG W, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19[J]. Nat Commun, 2021, 12(1):5417. DOI PMID
[26]	TRAHTEMBERG U, FRITZLER M J. On behalf of the COVID-19 chapter of the “Longitudinal Biomarkers in Lung Injury” study group. COVID-19-associated autoimmunity as a feature of acute respiratory failure[J]. Intensive Care Med, 2021, 47(7):801-804. DOI
[27]	CHANG S H, MINN D, KIM Y K. Autoantibodies in moderate and critical cases of COVID-19[J]. Clin Transl Sci, 2021, 14(5):1625-1626. DOI PMID
[28]	KAMPF G, VOSS A, SCHEITHAUER S. Inactivation of coronaviruses by heat[J]. J Hosp Infect, 2020, 105(2):348-349. DOI PMID

组别	例数	性别		年龄/岁	ORF1ab基因Ct值	N基因Ct值	NCT/d
组别	例数	男/例	女/例	年龄/岁	ORF1ab基因Ct值	N基因Ct值	NCT/d
ANA阳性组	24	13	11	75（33~90）	33.55±5.62	31.52±6.04	16（3~46）
ANA阴性组	25	10	15	67（26~88）	34.61±6.70	32.56±7.50	15（1~39）
统计值		0.987		-2.142	-0.597	-0.533	-0.200
P值		0.321		0.032	0.258	0.326	0.841

组别	例数	性别		年龄/岁	ORF1ab基因Ct值	N基因Ct值	NCT/d
组别	例数	男/例	女/例	年龄/岁	ORF1ab基因Ct值	N基因Ct值	NCT/d
ANA阳性组	24	13	11	75（33~90）	33.55±5.62	31.52±6.04	16（3~46）
ANA阴性组	25	10	15	67（26~88）	34.61±6.70	32.56±7.50	15（1~39）
统计值		0.987		-2.142	-0.597	-0.533	-0.200
P值		0.321		0.032	0.258	0.326	0.841

组别	例数	性别		年龄/岁	ORF1ab基因 Ct值	N 基因Ct 值	NCT/d	ANA阳性/ [例（%）]
组别	例数	男/例	女/例	年龄/岁	ORF1ab基因 Ct值	N 基因Ct 值	NCT/d	ANA阳性/ [例（%）]
合并AID组	9	2	7	56（33~83）	32.16±6.96	29.77±7.31	18（5~39）	5（55.6）
合并非AID组	31	18	13	71（26~90）	33.30±6.22	31.40±7.05	16（1~35）	15（48.4）
无基础疾病组	9	3	6	76（29~88）	38.76±1.53	36.58±2.36	12（3~46）	4（44.4）
统计值		4.417		6.952	7.501	5.889	1.879	0.234
P值		0.115		0.031	0.024	0.053	0.391	0.890

组别	例数	性别		年龄/岁	ORF1ab基因 Ct值	N 基因Ct 值	NCT/d	ANA阳性/ [例（%）]
组别	例数	男/例	女/例	年龄/岁	ORF1ab基因 Ct值	N 基因Ct 值	NCT/d	ANA阳性/ [例（%）]
合并AID组	9	2	7	56（33~83）	32.16±6.96	29.77±7.31	18（5~39）	5（55.6）
合并非AID组	31	18	13	71（26~90）	33.30±6.22	31.40±7.05	16（1~35）	15（48.4）
无基础疾病组	9	3	6	76（29~88）	38.76±1.53	36.58±2.36	12（3~46）	4（44.4）
统计值		4.417		6.952	7.501	5.889	1.879	0.234
P值		0.115		0.031	0.024	0.053	0.391	0.890